Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Roberto Adamo. (2014) Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives. Expert Review of Vaccines 13:7, pages 895-907.
Read now
Read now
Xiaopei Huang & Yiping Yang. (2010) Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses. Expert Opinion on Therapeutic Targets 14:8, pages 787-796.
Read now
Read now
Jean-Nicolas Tournier, Robert G Ulrich, Anne Quesnel-Hellmann, Mansour Mohamadzadeh & Bradley G Stiles. (2009) Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Review of Anti-infective Therapy 7:2, pages 219-236.
Read now
Read now
Pramod K Giri & Gopal K Khuller. (2008) Is intranasal vaccination a feasible solution for tuberculosis?. Expert Review of Vaccines 7:9, pages 1341-1356.
Read now
Read now
Debbie Higgins, Jason D Marshall, Paula Traquina, Gary Van Nest & Brian D Livingston. (2007) Immunostimulatory DNA as a vaccine adjuvant. Expert Review of Vaccines 6:5, pages 747-759.
Read now
Read now
Articles from other publishers (16)
Maya Holay, Nishta Krishnan, Jiarong Zhou, Yaou Duan, Zhongyuan Guo, Weiwei Gao, Ronnie H. Fang & Liangfang Zhang. (2022) Single Low-Dose Nanovaccine for Long-Term Protection against Anthrax Toxins. Nano Letters 22:23, pages 9672-9678.
Crossref
Crossref
Khalid Saad Alharbi, Mohammad Arshad Javed Shaikh, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi, Waleed Hassan almalki, Imran Kazmi, Fahad A. Al-Abbasi, Sami I. Alzarea, M Ravindra Babu, Sachin Kumar Singh, Dinesh Kumar Chellappan, Kamal Dua & Gaurav Gupta. (2022) Oligonucleotides: A novel area of interest for drug delivery in neurodegenerative diseases. Journal of Drug Delivery Science and Technology 77, pages 103849.
Crossref
Crossref
Veena V. Rao, C. Steven Godin, Michael J. Lacy, Jon R. Inglefield, Sukjoon Park, Bruna Blauth, Joshua J. Reece, Boris Ionin & Vladimir Savransky. (2021) Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations. International Journal of Toxicology 40:5, pages 442-452.
Crossref
Crossref
Jeffry D. Shearer, Lisa Henning, Daniel C. Sanford, Na Li, Mario H. Skiadopoulos, Joshua J. Reece, Boris Ionin & Vladimir Savransky. (2021) Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart. Vaccine 39:1, pages 1-5.
Crossref
Crossref
Meng-hung Tsai, Chuan-chang Chuang, Cheng-cheung Chen, Hui-ju Yen, Kuang-ming Cheng, Xin-an Chen, Huey-fen Shyu, Chia-ying Lee, Jenn-jong Young & Jyh-hwa Kau. (2020) Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: In vitro and in vivo efficacy in comparison to CpG. Carbohydrate Polymers 236, pages 116041.
Crossref
Crossref
Vladimir Savransky, Jeffry D. Shearer, Melicia R. Gainey, Daniel C. Sanford, Gloria S. Sivko, Gregory V. Stark, Na Li, Boris Ionin, Michael J. Lacy & Mario H. Skiadopoulos. (2017) Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate. Vaccine 35:37, pages 4952-4959.
Crossref
Crossref
Christopher K. Cote, Jared D. Heffron, Joel A. Bozue & Susan L. Welkos. 2015. Molecular Medical Microbiology. Molecular Medical Microbiology
1789
1844
.
Dianna Rynkiewicz, Melinda Rathkopf, Iain Sim, A. Thomas Waytes, Robert J. Hopkins, Lallan Giri, Deborah DeMuria, Janet Ransom, James Quinn, Gary S. Nabors & Carl J. Nielsen. (2011) Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers. Vaccine 29:37, pages 6313-6320.
Crossref
Crossref
Gerd Lipowsky & Martin F. Bachmann. 2011. Development of Vaccines. Development of Vaccines
19
63
.
Lissette S. Velasquez, Brooke E. Hjelm, Charles J. Arntzen & Melissa M. Herbst-Kralovetz. (2010) An Intranasally Delivered Toll-Like Receptor 7 Agonist Elicits Robust Systemic and Mucosal Responses to Norwalk Virus-Like Particles. Clinical and Vaccine Immunology 17:12, pages 1850-1858.
Crossref
Crossref
Yifan Ma, Louis Poisson, Guzman Sanchez‐Schmitz, Santosh Pawar, Chunfeng Qu, Gwendalyn J. Randolph, William L. Warren, Eric M. Mishkin & Russell G. Higbee. (2010)
Assessing the immunopotency of Toll‐like receptor agonists in an
in vitro
tissue‐engineered immunological model
. Immunology 130:3, pages 374-387.
Crossref
Crossref
Gregory E. D. Mullen, Ruth D. Ellis, Kazutoyo Miura, Elissa Malkin, Caroline Nolan, Mhorag Hay, Michael P. Fay, Allan Saul, Daming Zhu, Kelly Rausch, Samuel Moretz, Hong Zhou, Carole A. Long, Louis H. Miller & John Treanor. (2008) Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria. PLoS ONE 3:8, pages e2940.
Crossref
Crossref
Xueju Wang, Musheng Bao, Min Wan, Hongfei Wei, Li Wang, Hongtao Yu, Xuesong Zhang, Yongli Yu & Liying Wang. (2008) A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine 26:15, pages 1893-1901.
Crossref
Crossref
Christina C.N. Wu, Mojgan Sabet, Tomoko Hayashi, Rommel Tawatao, Joshua Fierer, Dennis A. Carson, Donald G. Guiney & Maripat Corr. (2008) In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model. Cellular Immunology 251:2, pages 78-85.
Crossref
Crossref
Thomas Müller, Svetlana Hamm & Stefan Bauer. 2008. Toll-Like Receptors (TLRs) and Innate Immunity. Toll-Like Receptors (TLRs) and Innate Immunity
51
70
.
Eric Soler & Louis-Marie Houdebine. 2007.
65
94
.